Blood Pressure Response to Zofenopril or Irbesartan Each Combined with Hydrochlorothiazide in High-Risk Hypertensives Uncontrolled by Monotherapy: A Randomized, Double-Blind, Controlled, Parallel Group, Noninferiority Trial
In this randomized, double-blind, controlled, parallel group study (ZENITH), 434 essential hypertensives with additional cardiovascular risk factors, uncontrolled by a previous monotherapy, were treated for 18 weeks with zofenopril 30 or 60 mg plus hydrochlorothiazide (HCTZ) 12.5 mg or irbesartan 15...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | International Journal of Hypertension |
| Online Access: | http://dx.doi.org/10.1155/2015/139465 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849435364786176000 |
|---|---|
| author | Ettore Malacco Stefano Omboni Gianfranco Parati |
| author_facet | Ettore Malacco Stefano Omboni Gianfranco Parati |
| author_sort | Ettore Malacco |
| collection | DOAJ |
| description | In this randomized, double-blind, controlled, parallel group study (ZENITH), 434 essential hypertensives with additional cardiovascular risk factors, uncontrolled by a previous monotherapy, were treated for 18 weeks with zofenopril 30 or 60 mg plus hydrochlorothiazide (HCTZ) 12.5 mg or irbesartan 150 or 300 mg plus HCTZ. Rate of office blood pressure (BP) response (zofenopril: 68% versus irbesartan: 70%; p=0.778) and 24-hour BP response (zofenopril: 85% versus irbesartan: 84%; p=0.781) was similar between the two treatment groups. Cardiac and renal damage was equally reduced by both treatments, whereas the rate of carotid plaque regression was significantly larger with zofenopril. In conclusion, uncontrolled monotherapy treated hypertensives effectively respond to a combination of zofenopril or irbesartan plus a thiazide diuretic, in terms of either BP response or target organ damage progression. |
| format | Article |
| id | doaj-art-e57ed9a411464322896686d3b3f7048b |
| institution | Kabale University |
| issn | 2090-0384 2090-0392 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Hypertension |
| spelling | doaj-art-e57ed9a411464322896686d3b3f7048b2025-08-20T03:26:20ZengWileyInternational Journal of Hypertension2090-03842090-03922015-01-01201510.1155/2015/139465139465Blood Pressure Response to Zofenopril or Irbesartan Each Combined with Hydrochlorothiazide in High-Risk Hypertensives Uncontrolled by Monotherapy: A Randomized, Double-Blind, Controlled, Parallel Group, Noninferiority TrialEttore Malacco0Stefano Omboni1Gianfranco Parati2L. Sacco Hospital, 20157 Milano, ItalyItalian Institute of Telemedicine, Solbiate Arno, 21048 Varese, ItalyIstituto Auxologico Italiano and University of Milano-Bicocca, 20149 Milano, ItalyIn this randomized, double-blind, controlled, parallel group study (ZENITH), 434 essential hypertensives with additional cardiovascular risk factors, uncontrolled by a previous monotherapy, were treated for 18 weeks with zofenopril 30 or 60 mg plus hydrochlorothiazide (HCTZ) 12.5 mg or irbesartan 150 or 300 mg plus HCTZ. Rate of office blood pressure (BP) response (zofenopril: 68% versus irbesartan: 70%; p=0.778) and 24-hour BP response (zofenopril: 85% versus irbesartan: 84%; p=0.781) was similar between the two treatment groups. Cardiac and renal damage was equally reduced by both treatments, whereas the rate of carotid plaque regression was significantly larger with zofenopril. In conclusion, uncontrolled monotherapy treated hypertensives effectively respond to a combination of zofenopril or irbesartan plus a thiazide diuretic, in terms of either BP response or target organ damage progression.http://dx.doi.org/10.1155/2015/139465 |
| spellingShingle | Ettore Malacco Stefano Omboni Gianfranco Parati Blood Pressure Response to Zofenopril or Irbesartan Each Combined with Hydrochlorothiazide in High-Risk Hypertensives Uncontrolled by Monotherapy: A Randomized, Double-Blind, Controlled, Parallel Group, Noninferiority Trial International Journal of Hypertension |
| title | Blood Pressure Response to Zofenopril or Irbesartan Each Combined with Hydrochlorothiazide in High-Risk Hypertensives Uncontrolled by Monotherapy: A Randomized, Double-Blind, Controlled, Parallel Group, Noninferiority Trial |
| title_full | Blood Pressure Response to Zofenopril or Irbesartan Each Combined with Hydrochlorothiazide in High-Risk Hypertensives Uncontrolled by Monotherapy: A Randomized, Double-Blind, Controlled, Parallel Group, Noninferiority Trial |
| title_fullStr | Blood Pressure Response to Zofenopril or Irbesartan Each Combined with Hydrochlorothiazide in High-Risk Hypertensives Uncontrolled by Monotherapy: A Randomized, Double-Blind, Controlled, Parallel Group, Noninferiority Trial |
| title_full_unstemmed | Blood Pressure Response to Zofenopril or Irbesartan Each Combined with Hydrochlorothiazide in High-Risk Hypertensives Uncontrolled by Monotherapy: A Randomized, Double-Blind, Controlled, Parallel Group, Noninferiority Trial |
| title_short | Blood Pressure Response to Zofenopril or Irbesartan Each Combined with Hydrochlorothiazide in High-Risk Hypertensives Uncontrolled by Monotherapy: A Randomized, Double-Blind, Controlled, Parallel Group, Noninferiority Trial |
| title_sort | blood pressure response to zofenopril or irbesartan each combined with hydrochlorothiazide in high risk hypertensives uncontrolled by monotherapy a randomized double blind controlled parallel group noninferiority trial |
| url | http://dx.doi.org/10.1155/2015/139465 |
| work_keys_str_mv | AT ettoremalacco bloodpressureresponsetozofenoprilorirbesartaneachcombinedwithhydrochlorothiazideinhighriskhypertensivesuncontrolledbymonotherapyarandomizeddoubleblindcontrolledparallelgroupnoninferioritytrial AT stefanoomboni bloodpressureresponsetozofenoprilorirbesartaneachcombinedwithhydrochlorothiazideinhighriskhypertensivesuncontrolledbymonotherapyarandomizeddoubleblindcontrolledparallelgroupnoninferioritytrial AT gianfrancoparati bloodpressureresponsetozofenoprilorirbesartaneachcombinedwithhydrochlorothiazideinhighriskhypertensivesuncontrolledbymonotherapyarandomizeddoubleblindcontrolledparallelgroupnoninferioritytrial |